Xiaoqinglong decoction combined with Yupingfeng powder alleviates combined allergic rhinitis and asthma syndrome by regulating the JAK2-STAT1-MHC II signaling pathway to suppress B lymphocyte activation.

ETHNOPHARMACOLOGICAL RELEVANCE: Xiaoqinglong Decoction combined with Yupingfeng Powder (XQLDwYPFP) is widely used to treat allergic rhinitis and bronchial asthma in Traditional Chinese Medicine, while its efficacy and mechanisms in combined allergic rhinitis and asthma syndrome (CARAS) remain underexplored.

AIM OF THE STUDY: To elucidate the mechanisms and pharmacodynamic basis of XQLDwYPFP in CARAS treatment.

MATERIALS AND

METHODS

A CARAS mouse model was established using ovalbumin (OVA). Airway allergic symptoms were assessed by recording nasal rubbing and sneezing frequencies. Serum OVA-sIgE levels were measured via ELISA. Histopathological changes were evaluated using HE, PAS, and C2R staining. Flow cytometry quantified Th cell subsets. Proteomics identified differential protein expression with GO and KEGG databases used for pathway enrichment analysis. Immunofluorescence assessed B lymphocyte activation, while Western blot and immunohistochemistry evaluated JAK1/JAK2-STAT1 pathway activation. Molecular docking validated the binding affinity of XQLDwYPFP components to JAK2 and STAT1.

RESULTS

XQLDwYPFP alleviated airway symptoms, reduced serum OVA-sIgE, and inhibited goblet cell hyperplasia and eosinophil infiltration in nasal and lung tissues. It decreased Th2 cell proportions and increased the Th1/Th2 ratio in lung and spleen tissues. Proteomics revealed that XQLDwYPFP suppresses CARAS by targeting the MHC II-mediated antigen presentation pathway. The formula reduced activated B lymphocytes and downregulated JAK2, p-JAK2, STAT1, and p-STAT1 expression in nasal and lung tissues. XQLDwYPFP representative components exhibited strong binding affinity to JAK2 and STAT1.

CONCLUSIONS

XQLDwYPFP alleviates type 2 inflammation in CARAS by regulating the JAK2-STAT1-MHC II pathway and inhibiting B lymphocyte-mediated antigen presentation. These findings provide novel pharmacological evidence supporting its clinical use for CARAS.